Prostate Cancer Market at a CAGR of 7.62% During the Forecast Period of 2025 to 2035

The Prevalence of Prostate Cancer Across the Globe to Boost the Global Prostate Cancer Market at a CAGR of 7.62% During the Forecast Period of 2025 to 2035

Prostate Cancer Market Overview

The global prostate cancer market demonstrates strong growth potential driven by rising incidence rates, increasing patient awareness, and advancements in diagnostic technologies and targeted therapies.

The prostate cancer market was valued at 7.35 USD billion in 2024 and is projected to reach 16.50 USD billion by 2035, reflecting sustained expansion throughout the forecast period.

Increasing adoption of novel theranostic approaches, rising availability of screening programs, and enhanced investment in oncology research support the market’s trajectory. Growing preference for minimally invasive and targeted therapies also contributes to demand.

Favorable reimbursement policies and active clinical development pipelines from global pharmaceutical leaders are further accelerating market penetration and treatment accessibility.

Segment Insights

Prostate cancer diagnosis and therapy are segmented by type into prostatic adenocarcinoma and small cell carcinoma. Small cell carcinoma held the majority share in 2022 due to the effectiveness of therapies that slow cancer progression by obstructing hormone activity essential for tumor growth.

Chemotherapy, biological therapy, and targeted therapy continue to be employed depending on disease progression and aggressiveness.

By component, the diagnosis segment dominated market share in 2022 and is expected to grow at a faster pace through 2030. Improved understanding of molecular alterations in prostate cancer and the emergence of personalized medicine approaches have increased reliance on diagnostics that enable accurate therapy selection.

Progress in imaging modalities and molecular biomarker discovery further enhances early detection capabilities. By end-user, hospitals and clinics accounted for the largest market revenue in 2022.

Rising patient inflow, wide availability of advanced diagnostic systems, and multidisciplinary treatment facilities reinforce their dominance. Specialty centers are also gaining traction as dedicated prostate cancer care units become more common, contributing to the market’s overall expansion.

Regional Insights

North America is expected to register significant CAGR growth during the forecast period due to increased incidence rates, robust screening programs, and higher adoption of advanced therapeutics. Approval of innovative treatments and strong R&D activities further strengthen regional dominance.

Europe represents the second-largest regional market owing to rising approvals for targeted therapies, growing patient population, and well-developed healthcare infrastructure. Increasing demand for advanced therapeutics, coupled with strategic collaboration among pharmaceutical companies, supports market growth.

The Asia-Pacific region is projected to record the fastest growth from 2025 to 2035. Increasing awareness regarding prostate cancer, a growing aging population, and rising investment from private and public healthcare bodies contribute to demand.

Expansion of medical infrastructure and adoption of advanced diagnostic capabilities further bolster growth.

Key Players

Leading companies operating in the prostate cancer market include Abbvie Inc., AstraZeneca, Bayer AG, Sanofi, IpsenPharma, Astellas Pharma Inc., Johnson & Johnson Services Inc., and Tolmar Pharmaceuticals Inc.

These companies emphasize extensive R&D investment, product portfolio expansion, and strategic collaborations to strengthen global market presence. Manufacturers are increasingly shifting to localized production and adopting cost-optimization strategies to enhance accessibility and expand market reach.

Industry Developments

·       In August 2023, the US FDA granted approval to FoundationOneCDx as a companion diagnostic for AKEEGA (abiraterone acetate + niraparib) developed by Janssen Pharmaceuticals, specifically targeting individuals with BRCA-positive metastatic castration-resistant prostate cancer.

·       In July 2023, Quest Diagnostics introduced a new biomarker test under AmeriPath after signing an agreement with Envision Sciences Pty Ltd., enabling more accurate prostate cancer identification.

Key Findings

·       The global prostate cancer market was valued at 7.35 USD billion in 2024 and is projected to reach 16.50 USD billion by 2035. The market is expected to grow at a CAGR of 7.63% from 2025 to 2035.

·       Small cell carcinoma remained the dominant type segment due to its responsiveness to targeted therapy approaches.

·       The diagnosis segment led the market and remained the fastest-growing component segment.

·       North America led the market due to high incidence rates and rapid adoption of novel therapies, while Asia-Pacific is anticipated to grow the fastest.

Get More Information about this Report: Prostate Cancer Market